132 records found.
Feb 06, 2020
Valo Therapeutics Announces New Funding for Immuno-Oncology Trials
Jan 15, 2020
New Medical Device That is Proving Effective Against the Worlds Toughest Viruses, Including: Ebola, Hep C, HIV, West Nile and Smallpox Wins FDA Designation "Breakthrough Device"
Dec 20, 2019
China's Largest Plasmid and Virus Facility from GenScript was Put into Operation
Dec 03, 2019
Novasep Launches oXYgene(TM), a Fully Integrated Offer for Boosting Viral Vector Production
Nov 14, 2019
Integral Molecular to Advance Vaccine Discovery with NIH Contract for $5.5M
Sep 24, 2019
Enesi Pharma Secures Innovate UK Funding to Enable Scalable Aseptic Manufacturing of ImplaVax®-enabled Solid Dose Viral Vector Vaccines
Sep 23, 2019
GenScript Partners with Harvard University to Develop Ultra-safe Cells Resistant to Natural Viruses
Sep 02, 2019
Valo Therapeutics Acquires PeptiENV Technology from the University of Helsinki
Aug 23, 2019
Study Uncovers a Strategy that Viruses use to Evade Immediate Immune Responses
Aug 20, 2019
Viral Vector and Plasmid DNA Manufacturing Market Size Worth US$ 1.8 Bn by 2026
Aug 14, 2019
Global Antiviral Therapeutics Delivery Research Report 2019: Analysis of Markets, 2018-2019 & Forecasts 2019-2028
Jun 17, 2019
Valo Therapeutics Appoints Michael Stein as Chief Executive Officer
Jun 11, 2019
Norovirus structures could help develop treatments for food poisoning
Jun 10, 2019
Technologies Enabling Next Generation Vaccine Development, 2019 - Upcoming Vaccine Technologies for Infectious Diseases
Jun 04, 2019
Antiviral Therapeutics Markets, 2028
May 28, 2019
Calidi Biotherapeutics Announces A Collaborative Study With The National Institutes Of Health (NIH) On The Therapeutic Potential Of Oncolytic Viruses Delivered By Mesenchymal Stem Cells
May 27, 2019
Technologies Enabling Next Generation Vaccine Development
May 23, 2019
Targovax to Fully Focus on ONCOS Oncolytic Virus Program
Apr 26, 2019
Global Viral Vector Manufacturing Markets Report 2019:The Market Accounted for $227.63 Million in 2017 and is Expected to Reach $1013 Million by 2026
Mar 27, 2019
The Global Virus Network (GVN) Launches Anticipation & Preparedness Taskforce Following 10th International Meeting in Annecy, France

Pages